Biotherapy Services
Biotherapy Services Limited is a multidisciplinary team of clinicians, scientists, pharmacists, and healthcare professionals focused on delivering safe and effective autologous biotherapies for wound healing and tissue regeneration. They utilize blood-derived products rich in white blood cells and platelets, harnessing the body's healing properties through state-of-the-art technology and proprietary processes to help patients in need. The company is involved in developing innovative treatments such as the RAPID™ Biodynamic Haematogel for complex and chronic wounds, including diabetic foot ulcers, pressure sores, and other non-healing wounds. They are engaged in clinical trials, regulatory approvals, and have received recognition such as the UK Innovation Passport. Their mission is to improve patient outcomes and reduce healthcare burdens through advanced regenerative therapies.
Industries
Nr. of Employees
small (1-50)
Biotherapy Services
The Clarence Centre for Enterprise & Innovation, 6 St George's Circus, London, SE1 6FE
Patents
Products
Autologous platelet‑rich gel wound treatment
A patient‑specific gel produced from concentrated autologous platelets and blood components, activated to release growth factors and applied topically to complex and chronic wounds to stimulate healing.
Autologous platelet‑rich gel wound treatment
A patient‑specific gel produced from concentrated autologous platelets and blood components, activated to release growth factors and applied topically to complex and chronic wounds to stimulate healing.
Services
Design, manage and operate randomized controlled clinical trials including multi‑site recruitment, clinical governance and trial treatment delivery for autologous wound care therapies.
Respond to clinician requests to supply investigational autologous therapies for individual patients outside of trials, in accordance with national guidance on unlicensed medicinal products.
Provide a mobile clinic service to deliver specialist wound care treatments and outreach services in non‑hospital settings.
Clinical provision of concentrated PRP formulations for aesthetic and reconstructive indications such as facial rejuvenation, scar revision, hair loss support and adjuncts to fat grafting.
Provide point‑of‑care manufacture of autologous medicinal products under national manufacturing licences and maintain associated quality systems and accreditations.
Design, manage and operate randomized controlled clinical trials including multi‑site recruitment, clinical governance and trial treatment delivery for autologous wound care therapies.
Respond to clinician requests to supply investigational autologous therapies for individual patients outside of trials, in accordance with national guidance on unlicensed medicinal products.
Provide a mobile clinic service to deliver specialist wound care treatments and outreach services in non‑hospital settings.
Clinical provision of concentrated PRP formulations for aesthetic and reconstructive indications such as facial rejuvenation, scar revision, hair loss support and adjuncts to fat grafting.
Provide point‑of‑care manufacture of autologous medicinal products under national manufacturing licences and maintain associated quality systems and accreditations.
Expertise Areas
- Clinical trial management for autologous therapies
- Point‑of‑care manufacturing of personalised medicines
- Autologous regenerative therapies (blood‑derived)
- GMP pharmaceutical manufacturing for clinical supply
Key Technologies
- Platelet‑rich plasma (PRP) processing
- Platelet‑rich fibrin / gel formulation
- Automated closed blood separation systems
- Sensor‑based cell‑type separation
News & Updates
Delveinsight Report names Biotherapy Services as one of the innovators in the diabetic foot ulcer market sector set to increase by 14.1% by 2030.
The company received the Innovation Passport for RAPID™ Biodynamic Haematogel, recognizing its potential to transform treatment of diabetic foot ulcers and other complex wounds.
BTS received a £1.5 million investment to support clinical development of their regenerative wound care treatment, particularly for diabetic foot ulcers.
Foresight Group invested £3 million into BTS, supporting the clinical trials and development of their innovative therapies for complex wounds.
Recognized as a groundbreaking treatment for diabetic foot ulcers, enabling accelerated development and access.
Delveinsight Report names Biotherapy Services as one of the innovators in the diabetic foot ulcer market sector set to increase by 14.1% by 2030.
The company received the Innovation Passport for RAPID™ Biodynamic Haematogel, recognizing its potential to transform treatment of diabetic foot ulcers and other complex wounds.
BTS received a £1.5 million investment to support clinical development of their regenerative wound care treatment, particularly for diabetic foot ulcers.
Foresight Group invested £3 million into BTS, supporting the clinical trials and development of their innovative therapies for complex wounds.
Recognized as a groundbreaking treatment for diabetic foot ulcers, enabling accelerated development and access.